International review of neurobiology最新文献_第4页

Psychological, physical and complementary therapies for the management of neuropathic pain. 治疗神经性疼痛的心理、物理和辅助疗法。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-11-01 DOI: 10.1016/bs.irn.2024.10.010

Nell Norman-Nott, Aidan G Cashin, Sylvia M Gustin

{"title":"Psychological, physical and complementary therapies for the management of neuropathic pain.","authors":"Nell Norman-Nott, Aidan G Cashin, Sylvia M Gustin","doi":"10.1016/bs.irn.2024.10.010","DOIUrl":"https://doi.org/10.1016/bs.irn.2024.10.010","url":null,"abstract":"This chapter aims to explain and evaluate the evidence for psychological, physical and complementary therapies as part of a holistic plan for managing neuropathic pain. Psychological therapies refer to interventions targeting mental health, while physical therapies refer to interventions designed to target movement and functional ability, and complementary therapies are those that attempt to target key mechanisms of change to alter brain and body functioning, or thought processes related to the experience of pain. Each therapeutic modality is discussed to narratively report on the evidence and provide implications for clinicians. Where evidence was unavailable for neuropathic pain populations, evidence from chronic pain populations more broadly was considered. Although promising, there is a lack of high-quality evidence investigating the benefits and safety of psychological, physical and complementary therapies for the management of neuropathic pain. The low certainty evidence and lack of evidence across different neuropathic pain conditions impacts the ability to make recommendations for clinical practice. However, there are several potential areas for future research. Psychological therapies that focus on the underlying mechanisms related to emotion regulation may improve mood and pain, while cognitive and behavioural based approaches may improve psychological comorbidities such as anxiety and depression. Physical therapies involving physical activity and exercise, education, and graded motor imagery may improve functioning and reduce pain. Finally, complementary therapies including electroencephalography neurofeedback, acupuncture, virtual reality, hypnosis and transcutaneous electrical nerve stimulation may provide promising reductions in pain. There is a clear need for further high-quality trials to evaluate the benefits and safety of psychological, physical and complementary therapies to guide the management of neuropathic pain.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"179 ","pages":"431-470"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142696222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modeling neuropathic pain in a dish. 在培养皿中模拟神经性疼痛

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-10-29 DOI: 10.1016/bs.irn.2024.10.003

Irene Zebochin, Franziska Denk, Zahra Nochi

{"title":"Modeling neuropathic pain in a dish.","authors":"Irene Zebochin, Franziska Denk, Zahra Nochi","doi":"10.1016/bs.irn.2024.10.003","DOIUrl":"https://doi.org/10.1016/bs.irn.2024.10.003","url":null,"abstract":"The study of pain mechanisms has advanced significantly with the development of innovative in vitro models. This chapter explores those already used in or potentially useful for neuropathic pain research, emphasizing the complementary roles of animal and human cellular models to enhance translational success. Traditional animal models have provided foundational insights into the neurobiology of pain and remain invaluable for understanding complex pain pathways. However, integrating human cellular models addresses the need for better replication of human nociceptors. The chapter details methodologies for culturing rodent and human primary sensory neurons, including isolation and culture techniques, advantages, and limitations. It highlights the application of these models in neuropathic pain research, such as identifying pain-associated receptors and ion channels. Recent advancements in using induced pluripotent stem cell (iPSC)-derived sensory neurons are also discussed. Finally, the chapter explores advanced in vitro models, including 2D co-cultures and 3D organoids, and their implications for studying neuropathic pain. These models offer significant advantages for drug screening and ethical research practices, providing a more accurate representation of human pain pathways and paving the way for innovative therapeutic strategies. Despite challenges such as limited access to viable human tissue and variability between samples, these in vitro models, alongside traditional animal models, are indispensable for advancing our understanding of neuropathic pain and developing effective treatments.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"179 ","pages":"233-278"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142696270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of oxytocin and vasopressin in alcohol use disorder. 催产素和血管加压素在酒精使用障碍中的作用。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-10-08 DOI: 10.1016/bs.irn.2024.08.006

Sutton M Scarboro, Marcelo F López, Howard C Becker

{"title":"Role of oxytocin and vasopressin in alcohol use disorder.","authors":"Sutton M Scarboro, Marcelo F López, Howard C Becker","doi":"10.1016/bs.irn.2024.08.006","DOIUrl":"10.1016/bs.irn.2024.08.006","url":null,"abstract":"Published works highlight the role of neuropeptides in both the development and treatment of AUD. Closely related hypothalamic neuropeptides, oxytocin (OT) and vasopressin (VP), initially recognized for their physiological hormone effects, are increasingly acknowledged for their behavioral influences. Studies consistently demonstrate that OT and VP impact alcohol consumption and related behaviors, implicating them in the neurobiology of addiction. Moreover, stress is a pivotal risk factor for alcohol use and relapse, with OT and VP playing an integral role in the body's stress response system. While previous work has explored the interaction of OT and VP with other substances of abuse, this review focuses on their roles in alcohol-associated behaviors specifically to better understand the role of OT and VP in AUD. Here we synthesize recent preclinical and clinical literature examining changes in OT and VP protein and receptor expression in response to alcohol, as well as research investigating the effects of modulating these systems on alcohol-related behaviors. This review aims to deepen the understanding of OT and VP in the context of AUD with the goal of facilitating future research and enhancing treatment outcomes.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"178 ","pages":"23-57"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cannabinoid for alcohol use disorder. 大麻素治疗酒精使用障碍。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-09-12 DOI: 10.1016/bs.irn.2024.08.005

Júlia Dalfovo Marquez, Talissa Dezanetti, Roger Walz, Cristiane Ribeiro de Carvalho

引用次数: 0

Environmental enrichment and complementary clinical interventions as therapeutic approaches for alcohol use disorder in animal models and humans. 将丰富环境和辅助临床干预作为治疗动物模型和人类酒精使用障碍的方法。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-08-28 DOI: 10.1016/bs.irn.2024.08.003

Rosana Camarini, Priscila Marianno, Beatriz Yamada Costa, Paola Palombo, Ana Regina Noto

{"title":"Environmental enrichment and complementary clinical interventions as therapeutic approaches for alcohol use disorder in animal models and humans.","authors":"Rosana Camarini, Priscila Marianno, Beatriz Yamada Costa, Paola Palombo, Ana Regina Noto","doi":"10.1016/bs.irn.2024.08.003","DOIUrl":"https://doi.org/10.1016/bs.irn.2024.08.003","url":null,"abstract":"Alcohol use disorder (AUD) is a multifactorial disorder arising from a complex interplay of various genetic, environmental, psychological, and social factors. Environmental factors influence alcohol misuse and can lead to AUD. While stress plays a crucial role in the onset and progression of this disorder, environmental enrichment (EE) also influences ethanol-induced behavioral and neurobiological responses. These alterations include reduced ethanol consumption, diminished operant self-administration, attenuated behavioral sensitization, and enhanced conditioned place preference. EE exerts modulatory effects on multiple neurobiological processes, such as the brain-derived neurotrophic factor/TrkB signaling pathway, the oxytocinergic system, and the hypothalamic-pituitary-adrenal axis. EE, which includes stimulating activities to counteract ethanol effects in animal studies, has parallels in human intervention that have shown potential benefits. Physical activity, cognitive behavioral therapy, and meditation, alongside techniques involving cognitive stimulation, social interaction, and recreational activities, may lead to more effective therapeutic outcomes in treatments of AUD.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"178 ","pages":"323-354"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Repurposing drugs for treatment of alcohol use disorder. 将药物重新用于治疗酒精使用障碍。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-03-12 DOI: 10.1016/bs.irn.2024.02.002

Henri-Jean Aubin

{"title":"Repurposing drugs for treatment of alcohol use disorder.","authors":"Henri-Jean Aubin","doi":"10.1016/bs.irn.2024.02.002","DOIUrl":"10.1016/bs.irn.2024.02.002","url":null,"abstract":"Repurposing drugs for the treatment of alcohol dependence involves the use of drugs that were initially developed for other conditions, but have shown promise in reducing alcohol use or preventing relapse. This approach can offer a more cost-effective and time-efficient alternative to developing new drugs from scratch. Currently approved medications for alcohol use disorder (AUD) include acamprosate, disulfiram, naltrexone, nalmefene, baclofen, and sodium oxybate. Acamprosate was developed specifically for AUD, while disulfiram's alcohol-deterrent effects were discovered incidentally. Naltrexone and nalmefene were originally approved for opioids but found secondary applications in AUD. Baclofen and sodium oxybate were repurposed from neurological conditions. Other drugs show promise. Topiramate and zonisamide, anticonvulsants, demonstrate efficacy in reducing alcohol consumption. Another anticonvulsant, gabapentin has been disappointing overall, except in cases involving alcohol withdrawal symptoms. Varenicline, a nicotinic receptor agonist, benefits individuals with less severe AUD or concurrent nicotine use. Ondansetron, a 5-HT3 antagonist, has potential for early-onset AUD, especially when combined with naltrexone. Antipsychotic drugs like aripiprazole and quetiapine have limited efficacy. Further investigation is needed for potential repurposing of α1 adrenergic receptor antagonists prazosin and doxazosin, glucocorticoid receptor antagonist mifepristone, the phosphodiesterase inhibitor Ibudilast, the cysteine prodrug N-acetylcysteine, and the OX1R and OX2R blocker Suvorexant. This review supports repurposing drugs as an effective strategy for expanding treatment options for AUD.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"175 ","pages":"153-185"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140330372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alcohol and the dopamine system. 酒精与多巴胺系统

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-03-13 DOI: 10.1016/bs.irn.2024.02.003

Bo Söderpalm, Mia Ericson

引用次数: 0

Current neuroprotective therapies and future prospects for motor neuron disease. 当前的神经保护疗法和运动神经元疾病的未来前景。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-05-16 DOI: 10.1016/bs.irn.2024.04.003

Laura J Evans, David O'Brien, Pamela J Shaw

{"title":"Current neuroprotective therapies and future prospects for motor neuron disease.","authors":"Laura J Evans, David O'Brien, Pamela J Shaw","doi":"10.1016/bs.irn.2024.04.003","DOIUrl":"10.1016/bs.irn.2024.04.003","url":null,"abstract":"Four medications with neuroprotective disease-modifying effects are now in use for motor neuron disease (MND). With FDA approvals for tofersen, relyvrio and edaravone in just the past year, 2022 ended a quarter of a century when riluzole was the sole such drug to offer to patients. The acceleration of approvals may mean we are witnessing the beginning of a step-change in how MND can be treated. Improvements in understanding underlying disease biology has led to more therapies being developed to target specific and multiple disease mechanisms. Consideration for how the pipeline of new therapeutic agents coming through in clinical and preclinical development can be more effectively evaluated with biomarkers, advances in patient stratification and clinical trial design pave the way for more successful translation for this archetypal complex neurodegenerative disease. While it must be cautioned that only slowed rates of progression have so far been demonstrated, pre-empting rapid neurodegeneration by using neurofilament biomarkers to signal when to treat, as is currently being trialled with tofersen, may be more effective for patients with known genetic predisposition to MND. Early intervention with personalized medicines could mean that for some patients at least, in future we may be able to substantially treat what is considered by many to be one of the most distressing diseases in medicine.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"176 ","pages":"327-384"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141159323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cannabidiol and epilepsy. 大麻二酚与癫痫。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-04-06 DOI: 10.1016/bs.irn.2024.03.009

Fabrício A Moreira, Antônio C P de Oliveira, Victor R Santos, Márcio F D Moraes

引用次数: 0

Molecular mechanisms of neuropathic pain. 神经性疼痛的分子机制

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-11-02 DOI: 10.1016/bs.irn.2024.10.002

Paola Pacifico, Daniela M Menichella

引用次数: 0